Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Integra Lifesciences Holdings Corp
IART
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$11.95
-0.38
-3.04%
Dern. MÀJ: Oct 23, 10:19 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Résultats:
Les résultats Q3 2026 ont été publiés le mer. oct. 21st, avant l'ouverture du marché
Conférence téléphonique:
La conférence téléphonique la plus récente a commencé à 8:30 AM, il y a 2 jours
Cliquez pour voir la webdiffusion
Integra Lifesciences Financials
Integra Lifesciences (IART) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Integra Lifesciences Q3 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $411.182M Miss $414.120M Estimate
Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 9.26 percent increase over earnings of $0.54 per share from
Benzinga Newsdesk
PRO
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634 billion-$1.654
Benzinga Newsdesk
PRO
Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.61-$0.71 vs $0.76 analyst estimate. sees sales of $413.000 million-$433.000 million vs $436.772 million analyst estimate.
Benzinga Newsdesk
Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook
Integra LifeSciences cut its 2026 financial guidance after a July flood disrupted its Cincinnati facility and negatively impacted revenue.
Vandana Singh
PRO
Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026
Benzinga Newsdesk
PRO
Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est
Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.53-$0.61 vs $0.56 analyst estimate. sees sales of $410.000 million-$425.000 million vs $418.100 million analyst estimate.
Benzinga Newsdesk
